iBio, Inc. (IBIO) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024 (Q1 of Fiscal Year 2025). iBio, Inc. is a preclinical-stage biotechnology company leveraging Artificial Intelligence (AI) and Machine Learning (ML) to develop precision antibodies for hard-to-drug targets. The company has completed its transition from a Contract Development and Manufacturing Organization (CDMO) to an AI-enabled biotech firm following the sale of its Texas CDMO facility in May 2024. Operations are now focused on its San Diego laboratory and its proprietary AI drug discovery platform.
Key Financial Metrics
| Metric | Q1 2025 (Sep 30, 2024) | Q1 2024 (Sep 30, 2023) |
|---|---|---|
| Revenue | $0 | $50,000 |
| Net Loss | $(3,989,000) | $(5,746,000) |
| Operating Loss | $(4,106,000) | $(5,103,000) |
| Cash & Equivalents | $11,038,000 | $4,561,000 (approx. based on cash flow end) |
| Total Assets | $24,517,000 | $28,734,000 (Prior Year End) |
| Total Liabilities | $6,763,000 | $7,410,000 (Prior Year End) |
| Accumulated Deficit | $(317,836,000) | $(294,686,000) |
| Net Cash Used in Operating Activities | $(3,715,000) | $(5,340,000) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero from $50,000 in the prior year quarter, as the company no longer recognizes revenue from its former CDMO operations and has not yet generated material revenue from its AI platform.
- Expense Reduction: Total operating expenses decreased by approximately $1.05 million (20%) to $4.1 million. This was driven by reduced personnel costs, lower insurance premiums, and decreased legal/consulting fees following the CDMO divestiture.
- Discontinued Operations: The prior year period included a loss of $672,000 from discontinued CDMO operations. No such losses were recorded in the current quarter as the CDMO was fully divested in May 2024.
- Liquidity Improvement: Cash and cash equivalents increased significantly to $11.0 million, bolstered by a private placement in April 2024 that raised approximately $14.1 million in net proceeds.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. The company has an accumulated deficit of $317.8 million and is currently burning approximately $1.1 million per month.
- Cash Runway: Management estimates current cash resources ($11.3 million including restricted cash) are sufficient to fund operations into the first quarter of Fiscal Year 2026, provided the burn rate is not increased or additional capital is raised.
- Financing Activities: The company entered into an "At Market" (ATM) issuance agreement in July 2024 with up to $7.35 million available for sale, though no shares were sold under this agreement as of September 30, 2024.
- Pipeline Progress: The company is advancing preclinical programs in obesity (anti-myostatin) and immuno-oncology (IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8). An initial manufacturing run for the anti-myostatin lead molecule was completed in November 2024 for non-human primate studies.
- Risks: Key risks include the inability to raise additional capital, potential impairment of indefinite-lived intangible assets (specifically the IBIO-101 IP valued at $5 million), and the failure of preclinical programs to advance to clinical trials.
Investor Verification Checklist
- Cash Burn Rate: Verify the monthly cash burn rate of ~$1.1 million against current cash balances to confirm the runway into Q1 FY2026.
- Capital Raise Status: Monitor the utilization of the ATM facility and any new equity offerings, as the company explicitly states it will need to raise additional capital to execute long-term plans.
- Intangible Asset Valuation: Review the annual impairment testing of the $5 million IBIO-101 indefinite-lived intangible asset, noting the sensitivity to stock price declines and FDA decisions on competitors.
- Debt Obligations: Confirm the status of the $933,000 term promissory note (Loeb Term Solutions) and equipment financing, including the balloon payment due in January 2026.
- Collaboration Milestones: Track the progress of the AstralBio collaboration regarding obesity targets and the potential exercise of options to license assets back to iBio.